Nora Q.E. Passamaneck

I'll research this attorney before drafting.

Nora Q.E. Passamaneck — Patent Litigation Practice Summary

Focus areas. Passamaneck's practice centers on intellectual property disputes at the pre-litigation, trial, and appellate stages, with a technology mix spanning pharmaceuticals and biologics, medical devices and wearable physiological sensors, microprocessors, telecommunications/networking, and internet and software technologies. Public docket activity confirms that range: the Apple/Masimo wearable-sensor and pulse-oximetry litigation, the Genentech/Amgen rituximab biosimilar dispute, and consumer-facing software and online-communications patent suits. Firm and CLE-published biographies also describe experience in trademark, ownership, and licensing disputes, and she has written on § 101/Alice motion practice and on Federal Circuit patent decisions.

Side preference. She works the defense side for operating companies. The tracked data shows 0 plaintiff-side and 1 defendant-side appearance, and the broader public record is consistent: she has represented Apple (Masimo v. Apple, Scramoge Technology v. Apple, and related matters), Twitter (the NPE suit Sampo IP, Inc. v. Twitter Inc., where she is listed as lead counsel, plus VidStream LLC v. Twitter), and Genentech as patent owner in the biosimilar dispute against Amgen. She does appear for patent owners in PTAB proceedings (see below), but no plaintiff-side NPE/PAE assertion practice is evident in the sources reviewed.

Firm context. She is a Wilmer Cutler Pickering Hale and Dorr partner based in Denver, and the tracked case list attributes her work to that firm. Her WilmerHale history is non-continuous: she was an associate in the firm's New York office from 2003–2007, served as career law clerk to the Hon. J. Michael Seabright (D. Haw.) and lectured at the University of Hawaii's William S. Richardson School of Law in 2010–2011, then rejoined WilmerHale in its Denver office in 2016 and later made partner. Note for currency: pro hac vice certificates and court filings from December 2025 onward identify her as a Senior Assistant Attorney General in the Colorado Office of the Attorney General, representing the State of Colorado in multistate litigation (e.g., State of California v. Noem, State of Maryland v. Hegseth). That suggests she has left private practice, though the tracked case data still lists WilmerHale; this transition is sourced to court filings and should be confirmed with her directly.

Notable cases; PTAB/IPR; bar and education. Her highest-profile tracked matter is Sampo IP, Inc. v. Twitter Inc. (D. Del., transferred to N.D. Cal.), an NPE suit asserting the "centrifugal communication and collaboration" patents. Beyond the tracked list, she was counsel of record for Apple in the long-running Masimo Corp. v. Apple Inc. patent dispute in the Central District of California, including the November 2025 trial phase and related ITC and Federal Circuit proceedings, and she supported Genentech's emergency TRO/preliminary injunction motion against Amgen in Delaware. On PTAB experience, she was conditionally admitted pro hac vice as back-up counsel for patent owner Celgene in Apotex Inc. v. Celgene Corp. (IPR2023-00512), has contributed to WilmerHale's post-grant practice programming (including a 2021 client webinar on Arthrex), and co-authors the firm's Federal Circuit patent case updates — indicating regular, though not lead-counsel, IPR exposure. She holds a JD, magna cum laude, from Boston University School of Law (executive editor, Boston University Law Review) and a BA in Biology with a Chemistry minor from New York University, and is admitted in Colorado, Massachusetts, and New York.

Caveats: the authoritative case list contains only one tracked appearance, so much of the above rests on public dockets, firm biographies, and court filings rather than the tracked dataset. Outcomes of the Masimo/Apple and Genentech/Amgen matters are not stated here because the sources reviewed did not establish them reliably; more complete docket verification would be needed before citing results.